Alicia Morgans, MD, on Treatment Options for Metastatic Castration-Sensitive Prostate Cancer July 15, 2020 Advances in upfront hormonal and chemohormonal therapy have driven a dramatic shift in treatment paradigms for metastatic castration-sensitive prostate cancer (mCSPC). At the same time, ongoing controversy around prostate-specific antigen screening practices, increased access to novel imaging modalities, and a globally aging population are driving increasing rates of this disease.Read the full article here.Source: Jeff Minerd - Medpage Today Prostate Cancer News
Advances in upfront hormonal and chemohormonal therapy have driven a dramatic shift in treatment paradigms for metastatic castration-sensitive prostate cancer (mCSPC). At the same time, ongoing controversy around prostate-specific antigen screening practices, increased access to novel imaging modalities, and a globally aging population are driving increasing rates of this disease.Read the full article here.Source: Jeff Minerd - Medpage Today
